JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB274929

Human EGR1 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

EGR1 KO cell line available to order. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9 X = 2 bp deletion Frameshift: 100%.

View Alternative Names

AT225, EGR1_HUMAN, Early growth response 1, Early growth response protein 1, G0S30, KROX 24, NGFI-A, Nerve growth factor-induced clone A, Nerve growth factor-induced protein A, TIS8, Transcription factor ETR103, Transcription factor Zif268, ZIF 268, ZNF225, Zinc finger protein 225, Zinc finger protein Krox-24

2 Images
Western blot - Human EGR1 knockout HeLa cell line (AB274929)
  • WB

Lab

Western blot - Human EGR1 knockout HeLa cell line (AB274929)

Lanes 1 - 4:

Western blot - Anti-Egr1 antibody [EPR15916] (<a href='/en-us/products/primary-antibodies/egr1-antibody-epr15916-ab194357'>ab194357</a>) at 1/10000 dilution

Lanes 1 - 4:

Western blot - Anti-Egr1 antibody [EPR15916] - BSA and Azide free (<a href='/en-us/products/primary-antibodies/egr1-antibody-epr15916-bsa-and-azide-free-ab232448'>ab232448</a>) at 1/10000 dilution

Lane 1:

Wild-type HeLa Vehicle Control TNF-a (0ng/mL, 1h) cell lysate at 20 µg

Lane 2:

Wild-type HeLa TNF-a (20ng/mL, 1h) cell lysate at 20 µg

Lane 3:

Western blot - Human EGR1 knockout HeLa cell line (ab274929)

Lane 3:

Western blot - Human EGR1 knockout HeLa cell lysate (ab274987)

Lane 3:

EGR1 knockout HeLa Vehicle Control TNF-a (0ng/mL, 1h) cell lysate at 20 µg

Lane 4:

EGR1 knockout HeLa TNF-a (20ng/mL, 1h) cell lysate at 20 µg

Secondary

All lanes:

Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution

Observed band size: 73 kDa

false

Next Generation Sequencing - Human EGR1 knockout HeLa cell line (AB274929)
  • NGS

Supplier Data

Next Generation Sequencing - Human EGR1 knockout HeLa cell line (AB274929)

Knockout achieved by CRISPR/Cas9; X = 2 bp deletion; Frameshift : 100%

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Next Generation Sequencing,Western blot

Mutation description

Knockout achieved by CRISPR/Cas9 X = 2 bp deletion Frameshift: 100%

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "NGS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Recommended control: Human wild-type HeLa cell line (ab271142). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab274929-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab274929 Human EGR1 knockout HeLa cell line", "number":"AB274929-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
EGR1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing, Western blot
Shipped at conditions
Dry Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
-196°C|-80°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Egr1 also known as early growth response protein 1 is a zinc-finger transcription factor with a molecular weight of approximately 60 kDa. The Egr1 protein plays a significant role in gene expression regulation by binding to specific DNA sequences. This target is highly expressed in a variety of tissues including the brain heart and kidneys. In these tissues Egr1 regulates several cellular processes by activating or repressing target genes. Also Egr1 has monoclonal antibodies available for research purposes providing tools for detailed study in specific cellular contexts.
Biological function summary

Egr1 acts as an immediate-early response gene. It gets rapidly upregulated in response to growth factors stress signals and other extracellular stimuli. As part of the cellular signaling networks Egr1 interacts with other transcription factors to control the expression of genes involved in cell differentiation proliferation and apoptosis. It does not typically form part of a protein complex but may work in concert with other signaling molecules to influence diverse cellular pathways and maintain cellular homeostasis.

Pathways

Egr1 is involved in the MAPK/ERK and PI3K/AKT signaling pathways both key to regulating cellular growth and survival. It functions as a bridging factor that links extracellular signals to transcriptional changes within the nucleus. In the MAPK/ERK pathway Egr1 works alongside proteins like Ras and MEK to promote early gene transcription in response to mitogenic signals. In the PI3K/AKT pathway Egr1 can influence downstream targets reinforcing the pathway's mechanisms in determining cell fate.

Egr1 is linked to cancer and cardiovascular diseases. Abnormal Egr1 expression and activity have been observed in various cancers where it can act as an oncogene or tumor suppressor depending on the context. Abnormal interactions with proteins such as p53 may contribute to tumorigenesis. In cardiovascular diseases Egr1 influences pathological states by regulating genes associated with inflammation and vascular remodeling. The protein's dysregulation plays a part in atherosclerosis connecting with inflammatory cytokines to promote disease progression.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com